Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company founded in 2014 by Alex Zhavoronkov. Originally incorporated in Baltimore and later headquartered in Hong Kong, the company applies generative AI, deep learning, and large-scale biological data to accelerate drug discovery and development across multiple disease areas including fibrosis, oncology, and aging-related conditions.

The company's primary platform, Pharma.AI, consists of three interconnected modules: PandaOmics for target discovery, Chemistry42 for AI-generated molecule design, and inClinico for clinical trial outcome prediction. Insilico's lead drug candidate, ISM001-055, a small molecule for idiopathic pulmonary fibrosis (IPF), was identified and designed using its AI platform and advanced into Phase II clinical trials — one of the first AI-generated drug candidates to reach that stage. The company has also disclosed multiple additional pipeline programs across oncology and other indications.

Insilico Medicine has raised approximately $410 million in total funding across several rounds, including a $95 million Series C in 2021 and a $60 million extension in 2022. The company employs several hundred people across offices in Hong Kong, the United States, the UAE, and China. In 2023, Insilico published Phase IIa results for ISM001-055, marking a notable milestone for AI-native drug discovery pipelines.